SSA therapy significantly enhanced the expression of p-CREB and BDNF, decreased the expression of Bax and Caspase-3, elevated the expression of Bcl-2, and inhibited the death of hippocampal neurons, thereby ameliorating depression-like behavior in PSD rats (Wang A. R. et al., 2021). Here, BDNF is linked to depressive symptom measurement.